晶泰控股(2228.HK)事件点评：AI制药平台“再下一城” 公司进入价值兑现期

Core Viewpoint - The announcement of RTX-117's clinical trial approval marks a significant milestone for Jingtai Technology and its collaboration with ReviR, showcasing the potential of AI and robotics in drug development for rare diseases [1][3]. Group 1: Clinical Development - RTX-117, a small molecule drug targeting Charcot-Marie-Tooth disease (CMT), has received clinical trial approval from the National Medical Products Administration, with plans to initiate Phase I trials in Q1 2026 [1]. - This drug is the first of its kind in China for CMT and represents the first clinical project from a series of rare disease drug pipelines developed through AI and robotic assistance [1]. Group 2: Technology and Business Model - The company has established a closed-loop model integrating quantum physics, AI, and robotics, enabling faster and more reliable drug development [2]. - The technology leverages first-principles calculations to simulate atomic and electronic interactions, generating high-precision virtual data even with limited training data [2]. - The company has developed over 200 AI vertical models, creating a robust algorithm engine, and has built a leading automated experimental platform for high-quality, high-throughput research data generation [2]. Group 3: Market Position and Financial Outlook - The company has formed long-term partnerships with 17 of the top 20 global pharmaceutical companies, validating the reliability and universality of its technology platform [3]. - In 2025, the company secured a pipeline collaboration worth nearly $6 billion with DoveTree, and reported a 404% year-on-year revenue growth in the first half of 2025, achieving profitability for the first time [3]. - Revenue projections for 2025-2027 are estimated at 785 million, 1.087 billion, and 1.485 billion yuan, reflecting year-on-year growth rates of 194.5%, 38.5%, and 36.6% respectively [3].